Online inquiry

IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15470MR)

This product GTTS-WQ15470MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Progressive supranuclear palsy (PSP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15470MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13527MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ7462MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ6306MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ5579MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7766
GTTS-WQ8201MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ7511MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ6219MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ5842MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ChAglyCD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW